These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8099612)

  • 1. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
    Dezube BJ; Pardee AB; Chapman B; Beckett LA; Korvick JA; Novick WJ; Chiurco J; Kasdan P; Ahlers CM; Ecto LT
    J Acquir Immune Defic Syndr (1988); 1993 Jul; 6(7):787-94. PubMed ID: 8099612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Dezube BJ; Lederman MM; Spritzler JG; Chapman B; Korvick JA; Flexner C; Dando S; Mattiacci MR; Ahlers CM; Zhang L
    J Infect Dis; 1995 Jun; 171(6):1628-32. PubMed ID: 7769305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells.
    Fazely F; Dezube BJ; Allen-Ryan J; Pardee AB; Ruprecht RM
    Blood; 1991 Apr; 77(8):1653-6. PubMed ID: 1707692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifylline for the treatment of HIV infection and its complications.
    Dezube BJ; Lederman MM
    J Cardiovasc Pharmacol; 1995; 25 Suppl 2():S139-42. PubMed ID: 8699854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship and prognostic value of endogenous interferon-alpha, beta 2-microglobulin, and neopterin serum levels in patients with Kaposi sarcoma and AIDS.
    Krown SE; Niedzwiecki D; Bhalla RB; Flomenberg N; Bundow D; Chapman D
    J Acquir Immune Defic Syndr (1988); 1991; 4(9):871-80. PubMed ID: 1895208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients.
    Luke DR; McCreedy BJ; Sarnoski TP; Bookout JB; Johnston AM; Lell JE; Wiggan EB; Bell N; Limjuco RA; Guthrie KI
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):343-50. PubMed ID: 8370633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV).
    Oie S; Jacobson MA; Abrams DI
    J Acquir Immune Defic Syndr (1988); 1993 May; 6(5):531-3. PubMed ID: 8097790
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
    Reddy MM; McKinley G; Englard A; Grieco MH
    Int J Immunopharmacol; 1990; 12(7):737-41. PubMed ID: 2127261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
    N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
    Krown SE; Gold JW; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew BJ
    Ann Intern Med; 1990 Jun; 112(11):812-21. PubMed ID: 1971504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate markers for AIDS treatment.
    Jacobson M
    Nurs Times; 1991 May 29-Jun 4; 87(22):49. PubMed ID: 1675013
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study.
    Landman D; Sarai A; Sathe SS
    Clin Infect Dis; 1994 Jan; 18(1):97-9. PubMed ID: 8054441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supportive pentoxifylline in falciparum malaria: no effect on tumor necrosis factor alpha levels or clinical outcome: a prospective, randomized, placebo-controlled study.
    Hemmer CJ; Hort G; Chiwakata CB; Seitz R; Egbring R; Gaus W; Hogel J; Hassemer M; Nawroth PP; Kern P; Dietrich M
    Am J Trop Med Hyg; 1997 Apr; 56(4):397-403. PubMed ID: 9158047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial.
    Wallis RS; Nsubuga P; Whalen C; Mugerwa RD; Okwera A; Oette D; Jackson JB; Johnson JL; Ellner JJ
    J Infect Dis; 1996 Oct; 174(4):727-33. PubMed ID: 8843209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
    Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R
    AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
    Siller L; Martin NL; Kostuchenko P; Beckett L; Rautonen J; Cheng SC; Wara DW
    AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection.
    Sathe SS; Sarai A; Tsigler D; Nedunchezian D
    J Infect Dis; 1994 Aug; 170(2):484-7. PubMed ID: 8035043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific.
    Krämer A; Biggar RJ; Hampl H; Friedman RM; Fuchs D; Wachter H; Goedert JJ
    Am J Epidemiol; 1992 Jul; 136(1):71-80. PubMed ID: 1384311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection.
    Fuchs D; Krämer A; Reibnegger G; Werner ER; Dierich MP; Goedert JJ; Wachter H
    Infection; 1991; 19 Suppl 2():S98-102. PubMed ID: 1673120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.